Balance Sheet Breakdown: Spyre Therapeutics Inc. (SYRE)’s Debt-to-Equity and Long-Term Debt/Eq Ratios

Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

After finishing at $25.63 in the prior trading day, Spyre Therapeutics Inc. (NASDAQ: SYRE) closed at $24.10, down -5.97%. In other words, the price has decreased by -$5.97 from its previous closing price. On the day, 1.61 million shares were traded. SYRE stock price reached its highest trading level at $26.54 during the session, while it also had its lowest trading level at $23.78.


Our goal is to gain a better understanding of SYRE by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.38 and its Current Ratio is at 11.38. In the meantime, Its Debt-to-Equity ratio is 1.66 whereas as Long-Term Debt/Eq ratio is at 1.66.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Robert W. Baird on May 02, 2024, initiated with a Outperform rating and assigned the stock a target price of $50.

On March 01, 2024, Wells Fargo Upgraded its rating to Overweight which previously was Equal Weight and also upped its target price recommendation from $12 to $35.

On December 20, 2023, BTIG Research started tracking the stock assigning a Buy rating and target price of $32.BTIG Research initiated its Buy rating on December 20, 2023, with a $32 target price.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SYRE now has a Market Capitalization of 1223855872 and an Enterprise Value of 671116288. For the stock, the TTM Price-to-Sale (P/S) ratio is 1773.62. Its current Enterprise Value per Revenue stands at 975.46 whereas that against EBITDA is -4.596.

Stock Price History:

Over the past 52 weeks, SYRE has reached a high of $47.97, while it has fallen to a 52-week low of $2.66. The 50-Day Moving Average of the stock is -30.35%, while the 200-Day Moving Average is calculated to be -0.94%.

Shares Statistics:

The stock has traded on average 426.47K shares per day over the past 3-months and 1006340 shares per day over the last 10 days, according to various share statistics. A total of 50.78M shares are outstanding, with a floating share count of 44.99M. Insiders hold about 11.40% of the company’s shares, while institutions hold 64.69% stake in the company. Shares short for SYRE as of 1715731200 were 4517727 with a Short Ratio of 10.73, compared to 1713139200 on 3555205. Therefore, it implies a Short% of Shares Outstanding of 4517727 and a Short% of Float of 14.35.

Most Popular